Physician profile
Moises Riveron
NPI 1386012003
$7,713.15
in general payments reported to CMS, 2019-2025
15 companies · $1,497 in 2025
The $1,497 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $824 · 2021: $1,122 · 2022: $1,519 · 2023: $934 · 2024: $1,090 · 2025: $1,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,410 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,409.76 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,668.02 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $1,212.64 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $1,146.60 | 2020-2024 | Perseris |
| Abbvie INC. | $964.16 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $913.51 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Allergan, INC. | $475.65 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $470.27 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $319.38 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $241.82 | 2023-2025 | Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.11 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $58.45 | 2019-2023 | Hetlioz, Fanapt |
| Lundbeck LLC | $46.13 | 2022-2023 | Rexulti |
| Sanofi Pasteur INC. | $26.40 | 2024 | |
| Axsome Therapeutics, INC. | $24.73 | 2024 | Auvelity |
| Shire North American Group INC | $16.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moises Riveron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.